Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is partnering with Kymanox as the company prepares a pre-Investigational New Drug (“IND”) package and meeting request with the United States Food and Drug Administration (“FDA”). Silo made the decision to move forward after receiving positive SPC-15 preclinical data. Silo’s SPC-15 uses metabolic biomarker profiling to treat anxiety, PTSD and other stress-related disorders. Kymanox is a full-service life sciences solutions provider that offers regulatory affairs support to companies developing a clinical pharmacology and biopharmaceutics strategy and program to be proposed to the FDA. Silo noted that it plans to file a pre-IND meeting request for collaborative discussions with the FDA by early next year.

“Our preclinical data indicate that SPC-15 has additive benefits for combating stress-induced pathophysiology, both at the behavioral and neural levels,” said Silo Pharma founder and CEO Eric Weisblum in the press release. “In conjunction with Columbia University, we are pleased to announce this milestone in advancing our potential therapeutic development for those suffering from stress-induced anxiety and PTSD. We are confident that our own preclinical work coupled with published preclinical data provides a strong foundation for our pre-IND application, which we plan to submit during the first quarter of 2024.”

To view the full press release, visit https://ibn.fm/ueAQB

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that the company believes will be transformative to the well-being of patients and the healthcare industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN